Reeves and the Government need ... a turbulent week for big pharma as Donald Trump questioned drug pricing in the US. Keir Starmer is so obsessed with keeping on good terms with the US President ...

For instance, according to the US Government ... very good at research, not necessarily at developing or commercialising their brands,” he said. “Conversely, when you are a big pharma company ...

A survey of small-to-medium pharma companies ... or no confidence” in the government’s handling of Brexit negotiations, and nearly two-thirds believe a ‘good’ deal won’t be achieved ...

In signing an executive order aimed at reducing U.S. drug prices, President Donald Trump said some prices would be cut in ...

Most voters, 50% to 38%, said it would be "good for Americans if the government paid for most health care and could therefore decide which drugs would or would not be available," the press release ...

The Trump administration has been unrelenting in its campaign to lower drug prices and onshoring the pharmaceutical industry's supply chain. On Thursday, a special adviser to the Trump ...

The government has already granted them a review. None of this should surprise us. Why wouldn’t Big Pharma latch on to the opportunity of Trump’s tariff threats to make price-gouging easier, even if ...

Several big pharma firms are pledging to boost output in America in response to the tariff threat. Johnson & Johnson plans to invest $55bn, Roche $50bn, Eli Lilly $27bn and Novartis $23bn over the ...

This is misleading. Prices for most prescription drugs — unbranded generics are the exception — are higher in the U.S. than ...